The RAD52 S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations

Women who carry pathogenic mutations in BRCA1 and BRCA2 have a lifetime risk of developing breast cancer of up to 80%. However, risk estimates vary in part due to genetic modifiers. We investigated the association of the RAD52 S346X variant as a modifier of the risk of developing breast and ovarian...

Descripción completa

Detalles Bibliográficos
Autores principales: Adamson, Aaron W., Ding, Yuan Chun, Mendez‐Dorantes, Carlos, Bailis, Adam M., Stark, Jeremy M., Neuhausen, Susan L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266271/
https://www.ncbi.nlm.nih.gov/pubmed/32175645
http://dx.doi.org/10.1002/1878-0261.12665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266271/
https://www.ncbi.nlm.nih.gov/pubmed/32175645
http://dx.doi.org/10.1002/1878-0261.12665

Ejemplares similares